ARTICLE | Product Development

A patch for Parkinson's

October 18, 2004 7:00 AM UTC

Schwarz Pharma AG's Neupro rotigotine dopamine receptor agonist for Parkinson's disease may have an advantage over marketed compounds in the same class because it is administered once daily using a patch. By comparison, marketed dopamine receptor agonists are dosed orally three times daily.

Schwarz reported additional Phase III data last week after having applied for marketing authorizations for Neupro in the U.S. and Europe last month. In the U.S. Phase III trial in 351 advanced PD patients, Neupro plus levodopa met the co-primary endpoints of an absolute reduction in the number of patients who experienced off-time compared to baseline and a 30% reduction in off-time compared to baseline (see B10). ...